Drug intelligence / Profile preview

OCU520

Development stage: Preclinical
Lead developer: Ocugen
Modality: Vaccines & Immunotherapeutics
Administration: Inhalation

Overview

OCU520 is a combination quadrivalent seasonal flu and COVID-19 vaccine developed by Ocugen. It is part of a next-generation, inhalation-based mucosal vaccine platform that utilizes a novel chimpanzee adenovirus (ChAd) vector. This vaccine aims to induce an immune response against both seasonal influenza and COVID-19 through mucosal delivery.

Beyond the preview

Go deeper on OCU520.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCU520.

Explore the full profile